BACKGROUND AND OBJECTIVES: This study is to find out whether laser tympanostomy (LT) with tympanostomy tube (TT) insertion has some potential role for the treatment of children with chronic otitis media with effusion (OME) under the topical anesthesia. SUBJECTIVES AND METHOD: We prospectively enrolled 89 OME children (2-7 yrs old, 139 ears) for LT with TT insertion under topical anesthesia. Following LT, TT insertion was done if the middle ear effusion was mucoid or if middle ear mucosa was inflammed, or if the child had poor prognostic factors. RESULTS: Ninety-four ears (68%) had mucoid effusion, 18 ears (13%) serous effusion, 11 ears (8%) purulent effusion, and 16 ears (12%) were dry. It was determined that TT insertion was not necessary in 26 ears (19%). TT insertion into the laser tympanostomy opening was tried on the other 113 ears. TT insertion had a success rate of 81% (91/113). After 3 months of follow-up, LT that did not need TT insertion showed 81% (21 ears) resolution rate. Therefore, the total efficacy of LT with TT insertion under topical anesthesia was 85%. CONCLUSION: Laser tympanostomy with TT insertion resulted in increased efficacy. Also, compared to knife myringotomy, it seems to have a potential role for lowering the age group of OME children whom can be managed under topical anesthesia.
Anesthesia* ; Child ; Ear ; Ear, Middle ; Follow-Up Studies ; Humans ; Middle Ear Ventilation* ; Mucous Membrane ; Otitis Media with Effusion ; Prospective Studies ; Treatment Outcome* ; Ventilation*

Thymic hyperplasia results from thymic regrowth after atrophy during a stressful period. Differentiation from recurrent or residual neoplasm may be an important consideration. Thymic hyperplasia is most problematic when it is observed in patients with malignant lymphoma. We report a case of thymic hyperplasia in which thymic enlargement is developed in a malignant lymphoma patient with high-dose chemotherapy and autologous peripheral blood stem cell transplantation and this condition is confirmed by the findings of serial chest computed tomography without chemotherpy.
Atrophy ; Drug Therapy* ; Humans ; Lymphoma* ; Neoplasm, Residual ; Peripheral Blood Stem Cell Transplantation ; Thorax ; Thymus Hyperplasia*

Despite an aggressive surgical debulking followed by front-line chemotherapy, most patients with advanced ovarian carcinoma die of drug-resistant disease. Drug resistance can be overcome in a subset of patients with hematologic malignancies and lymphoma with high-dose therapy (HDT) and hematopoietic stem cell transplantation, suggesting that this therapy may also be value in ovarian carcinoma. We report the successful outcome of HDT and peripheral blood stem cell transplantation (PBSCT) in a 41-year-old nulliparous woman who initially was diagnosed with advanced ovarian carcicnoma with FIGO stage IIIc. Her disease relapsed after 19 months from initial therapy of definitive surgery and intra- and post-operative chemotherapy. Subsequently, she received optimal debulking surgery and salvage chemotherapy followed by HDT with triple- alkylating regimen, composed of cyclophosphamide (100 mg/kg), thiotepa (500 mg/m2), and melphalan (100 mg/m2). Her pretranplant characteristics were platinum-sensitive and complete response state. She showed rapid hematologic recovery and mild regimen-related toxicity (Bear man's toxicity criteria), stomatitis (grade I), cardiac toxicitiy (grade II). She has been followed up for 36 months after the inital therapy and is doing well without relapse.
Adult ; Cyclophosphamide ; Drug Resistance ; Drug Therapy ; Female ; Glycogen Storage Disease Type VI ; Hematologic Neoplasms ; Hematopoietic Stem Cell Transplantation ; Humans ; Lymphoma ; Melphalan ; Ovarian Neoplasms ; Peripheral Blood Stem Cell Transplantation* ; Recurrence ; Stomatitis ; Thiotepa

PURPOSE: We tried to evaluate the clinical usefullness of fractionated low-dose infusions of peripheral blood stem cells (PBSCs) as a supportive care. MATERIALS AND METHODS: Four patients were entered onto this study who were diagnosed to have gastric lymphoma (n=1) and advanced ovarian carcinomas (n=3). To overcome the hematologic toxicities, G-CSF-mobilized PBSCs were collected early in disease course. Harvested products were cryopreserved in aliquotes and then infused after each cycle. Planned therapeutic schedules should be performed without changes of dose and interval regardless of hematologic toxicities. RESULTS: 20 cycles of chemotherapies were performed and data of infused cell doses were as follows: median number of PBSCs infusions, 4.5 (3~5); median MNCs, CFU-GM colony counts per infusion of low-dose PBSCs, 1.7 108/kg (1.0~2.4), 3.2 104/kg (2.1~11.8). Among 20 cycles, delayed recovery of thrombocytopenia was shown on 10 cycles. Leukopenia (III/IV) and thrombocytopenia (III/IV) were shown on 8/6 cycles and 8/2 cycles. In spite of myelosuppression, they were successfully treated with planned dose-intensity. Especially incomplete platelet recovery was successfully rescuced by using fractionated infusions of low-dose PBSCs. CONCLUSION: These data warrant further clinical trials to evaluate the potentials of fractionated low-dose infusions of PBSCs collected early in disease course for overcoming accumulated hematologic toxicities, especially thrombocytopenia complicated by repeated chemotherapies.
Appointments and Schedules ; Blood Platelets ; Drug Therapy ; Drug Therapy, Combination* ; Granulocyte-Macrophage Progenitor Cells ; Humans ; Leukopenia ; Lymphoma ; Stem Cells* ; Thrombocytopenia

PURPOSE: Bisphosphonates have been used to treat osteoporosis for more than ten years. However, complications associated with long-term administration of bisphosphonates, such as nonunion after pelvic insufficiency fracture or osteonecrosis of the jaw, have been recently reported in the literature. We investigated the relationships among the mechanical properties of the intact rat femur as well as healing fracture calluses and the intraosseous concentration of pamidronate (ICP), after long-term administration of pamidronate in a rat osteoporosis model. MATERIALS AND METHODS: We performed bilateral ovariectomy in 25 3-month-old female Sprague-Dawley rats. Beginning three months after ovariectomy, disodium pamidronate (0.5mg/kg) was injected every month. After the six-month administration period, the left femoral shaft was fractured using the closed fracture technique. Five weeks after fracture, 23 rats were euthanized and both femora were removed. We checked the mechanical properties of the intact (right) and fractured (left) femora using a three-point bending technique. Intraosseous concentration of pamidronate was checked by high-performance liquid chromatography. RESULTS: The mean ICP was 61.8+/-15.7ng/mg of bone. High ICP decreased the ultimate load to failure, stiffness, and ultimate stress of the intact femora (p=0.015, 0.027, 0.039, respectively). There was a tendency to decrease the ultimate load to failure in the healing callus when the ICP increased (p= 0.183). High ICP decreased the bone mineral density of the femoral head (p=0.005). CONCLUSION: High concentrations of pamidronate in intact bone decreased the bone mineral density and weakened the mechanical strength of the rat femora. The mechanical strength of the early healing callus was not correlated with concentration of pamidronate in the bone.
Animals ; Bone Density Conservation Agents/*pharmacology ; Diphosphonates/*pharmacology ; Disease Models, Animal ; Female ; Femur/*drug effects/physiology ; Fracture Healing/physiology ; Osteoporosis/*metabolism ; Rats ; Rats, Sprague-Dawley ; Stress, Mechanical

PURPOSE: Cryopreservation has been the standard method of storing hematopoietic cells for the past 20 years, but this prdegrees Cedure is laborious and expensive. So, we evaluated the hematopoietic recovery of stored PBSCs at 4degrees C for a variable storage period MATERIALS AND METHODS: Eight leukapheresis products were kept unprdegrees Cessed at 4degrees C for 96 hours. To evaluate the effect of storage period on the hematopoietic recovery of PBSCs, assays for viability of mononuclear cells (MNCs), CFU-GM colony counts and CD34 cell counts were performed every 24 hours after PBSC collection. We tried to compare hematopoetic recovery of stored PBSCs at 4degrees C with that of cryopreserved PBSCs by using repeated measures ANOVA. RESULTS: Viability of MNCs, CFU-GM colony counts and CD34 cell counts were monitored at 24 hour, 48 hour, 72 hour and 96 hour after PBSC collection. Data are expressed as percentage of baseline value and shown as mean s.d.; MNCs viability (96+/-2%, 94+/-2%, 92+/-2%, 88+/- 3%), CFU-GM colony counts (87+/-10%, 79+/-11%, 65+/-13%, 56+/-15%), and CD34 cell counts (93+/-13%, 93+/-12%, 88+/-14%, 85+/-19%). After storing PBSCs at 4degrees C for 96 hours, viability of MNCs and CFU-GM colony counts were significantly reduced (p<0.05) except CD34 cell concentration (p>0.05). Prdegrees Cedures of controlled-rate freezing and thawing resulted in a notable loss of viability (77+/-9%) and CFU-GM colony count (71+/-29%). CFU-GM colony counts of 72 hour-stored PBSCs at 4degrees C was similar to those of cryopreserved PBSCs. CONCLUSION: If G-CSF mobilized PBSCs are stored at 4degrees C in less than 72 hours after collection, those hematopoietic recovery would be comparable to that of cryopreserved stem cells which are achieved by the rate-control freezer.
Bezafibrate ; Cell Count ; Cryopreservation ; Freezing ; Granulocyte Colony-Stimulating Factor ; Granulocyte-Macrophage Progenitor Cells ; Leukapheresis ; Stem Cells*

We describe the case of a 70-year old female who had developed acute renal failure following high dose methotrexate therapy for malignant lymphoma. Previously, she showed normal renal function and tolerance to high dose methotrexate therapy. Serum methotrexate level reached 9.25 micro mol/L and sustained elevated level for 1 week, although folic acid rescue was intensified to 150 mg intravenously every 3 hours. Therefore, 3 times total plasma exchange and one hemodialysis were performed, and serum methotrexate level returned to normal range. Acute renal failure induced by methotrexate can be complicated by prolonged high serum level of methotrexate, resulting in bone marrow suppression and severe mucositis. To lower the serum methotrexate level, dialysis, plasma exchange, hemoperfusion with charcoal only or combined with hemodialysis and carboxypeptidase-G2 were tried. Successful rescue was obtained by plasma exchange and hemodialysis. No rebound phenomenon was developed.
Acute Kidney Injury* ; Aged ; Bone Marrow ; Charcoal ; Dialysis ; Female ; Folic Acid ; Hemoperfusion ; Humans ; Lymphoma ; Methotrexate ; Mucositis ; Plasma Exchange* ; Plasma* ; Reference Values ; Renal Dialysis*